In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 131 to 140 of 301

TitleTypeExpected publication date
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidanceTBC
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]Technology appraisal guidanceTBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Technology appraisal guidanceTBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidanceTBC
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment (review of TA987) [ID6619]Technology appraisal guidance
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All